Moonwalk Biosciences announces $70M Series B to advance adipose-targeted RNai therapies
Moonwalk Biosciences announced a $70 million Series B financing to advance adipose-targeted RNai therapies for obesity and cardiometabolic diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.